Understand the impact of robotic-assisted prostate cancer surgery and real-time analysis on surgical precision and patient ...

The Prostate Cancer Foundation (PCF) celebrated groundbreaking progress and innovation in the fight against prostate cancer at its 32nd Annual PCF Scientific Retreat, held October 23-25, 2025, in ...

In a significant policy reversal, the National Institute for Health and Care Excellence (NICE) has recommended abiraterone ...

We estimate the NHS could potentially save £millions annually by greater use of the generic version of abiraterone rather than using enzalutamide and apalutamide, the other treatments we recommend at ...

President Donald Trump is meeting face-to-face with Chinese leader Xi Jinping on Thursday, a chance for the leaders of the ...

When it comes to health, sometimes you have to start in the middle. "We believe in treating the whole person because the pelvis is literally the middle of the body," said Physical Therapist Erica ...

The Radioligand Therapy Market is projected to reach US$13 billion by 2030, growing at an estimated rate of ~5%. Key drivers of this growth include the rising incidence of cancers such as prostate ...

The UK’s National Health Service (NHS) is set to pilot an AI-driven “one-day diagnostics” service for prostate cancer that ...

Fast growth for recently label-expanded drugs fuelled Novartis’ Q3 performance, despite headwinds from generic competition.

Adding Pluvicto to standard therapy in metastatic patients led to a radiographic PFS benefit, but questions remain about ...

Clarity Pharmaceuticals Ltd. (($AU:CU6)) announced an update on their ongoing clinical study. Clarity Pharmaceuticals Ltd. is conducting a Phase 3 ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...